Key result
Impaired myocardial blush grade (MBG-0/1) after PCI for NSTE-ACS predicted higher 30-day net adverse clinical events compared to MBG-2/3, but not 1-year outcomes.
Why the study?
Does post-procedural myocardial blush grade (MBG) predict short- and long-term clinical outcomes in patients undergoing PCI for NSTE-ACS?
RCT (n=3,115)
Does post-procedural myocardial blush grade (MBG) predict short- and long-term clinical outcomes in patients undergoing PCI for NSTE-ACS?
In patients with NSTE-ACS undergoing PCI, impaired myocardial blush grade predicts 30-day revascularization but does not stratify 1-year outcomes, unlike its prognostic value in STEMI.
Answers are grounded in this paper and cite their sources.
Impaired post-PCI MBG may aid short-term risk stratification in NSTE-ACS; leaves open long-term utility and prospective validation.
OBJECTIVE: We evaluated the ability of post-procedural myocardial blush grade (MBG) to stratify outcomes of patients undergoing percutaneous coronary intervention (PCI) for non-ST segment elevation acute coronary syndromes (NSTE-ACS). BACKGROUND: MBG strongly correlates with survival after reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). METHODS: Of 13,819 NSTE-ACS patients randomized in the ACUITY trial, 3,115 patients underwent PCI and had MBG analyzed by an independent angiographic core laboratory. We examined net adverse clinical events (NACE; composite ischemia or bleeding), composite ischemia (death, MI or ischemia-driven revascularization) and non-CABG major bleeding according to final MBG. RESULTS: At 30 days, patients with MBG-0/1 had higher rates of NACE (25.1% vs. 13.9%, P = 0.002) and composite ischemia (19.1% vs. 9.4%, P = 0.002) than patients with MBG-2/3. At 1-year follow-up, MBG-0/1 patients had significantly higher rates of composite ischemia compared to other patients (27.8% vs. 19.8%, P = 0.02). By multivariable analysis, MBG-0/1 was an independent predictor of 30-day ischemia-driven revascularization (OR 5.74 [2.63, 12.54], P < 0.0001) in the total population and among patients with normal post-PCI epicardial TIMI-3 flow (OR 6.39 [2.06, 19.78], P = 0.001). However, 1-year outcomes were similar between patients with and without normal myocardial perfusion. CONCLUSIONS: In conclusion, MBG is a predictor of 30-day revascularization in the overall population and in patients with normal epicardial flow but fails to stratify 1-year outcomes. Thus, unlike in STEMI patients, the prognostic value of MBG in NSTE-ACS patients appears to be limited to the short-term.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2015) conducted an RCT in Non-ST segment elevation acute coronary syndromes (NSTE-ACS) (n=3,115). Myocardial blush grade 0/1 (impaired perfusion) vs. Myocardial blush grade 2/3 (normal perfusion) was evaluated on Net adverse clinical events (NACE; composite ischemia or bleeding) at 30 days (p=0.002). Impaired myocardial blush grade (MBG-0/1) after PCI for NSTE-ACS predicted higher 30-day net adverse clinical events compared to MBG-2/3, but not 1-year outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: